Loading
companiesCompany
Fate Therapeutics
Fate Therapeutics builds iPSC-derived off-the-shelf CAR-T and CAR-NK cells (FT819, FT522) for cancer and autoimmune disease.
Overview
Fate Therapeutics, based in San Diego and listed as FATE, builds off-the-shelf CAR-T and CAR-NK cells derived from induced pluripotent stem cells, including FT819 and FT522, for cancer and autoimmune disease. FT819 is a clonal iPSC-derived CD19 CAR-T, FT522 is a CD19 CAR-NK with alloimmune defence receptors designed to avoid conditioning chemotherapy, the company presented at ASCO and EULAR 2026, and it has a solid-tumour collaboration with Ono. OnCo links it to diffuse large B-cell lymphoma, to allogeneic cell therapy, CAR-NK and CAR-T, to CD19 as a target and to ideas on qualifying one iPSC master cell bank for many products. Manufacturing cost and time for living medicines is the bottleneck iPSC-derived cells are meant to relieve. Whether iPSC-derived cells persist and perform as well as patient-derived ones is the open question.
Similar pages
- CompanyCaribou Biosciences
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanySana Biotechnology
Shares Qualify one iPSC master cell bank once for many off-the-shelf cell products, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanyNkarta
Shares Off-the-shelf natural killer cells to sweep up residual disease, CAR-NK & CAR-macrophage, CD19, Diffuse large B-cell lymphoma.
- CompanyCentury Therapeutics
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- PersonKatayoun Rezvani
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, CD19, Diffuse large B-cell lymphoma.
- CompanyCellogen Therapeutics
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- TechnologyNK cell therapy and CAR-NK
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Diffuse large B-cell lymphoma.